Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer

European Journal of Clinical Investigation

Volumn 43, Issue 3, 2013, Pages 286-291

  Arnold, Tobias ^a   Michlmayr, Anna ^a   Baumann, Suzann ^a   Burghuber, Christopher ^a   Pluschnig, Ursula ^a   Bartsch, Rupert ^a   Steger, Guenther ^a   Gnant, Michael ^a   Bergmann, Michael ^a   Bachleitner Hofmann, Thomas ^a   Oehler, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Cell death; Docetaxel; Epirubicin; HMGB1; Predictive marker

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; LACTATE DEHYDROGENASE;

ADD ON THERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EPIRUBICIN; FEMALE; HMGB1 PROTEIN; HUMANS; NEOADJUVANT THERAPY; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 84873998443     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12043     Document Type: Article

References (17)

1. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
2. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000;11:647-63.
3. Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C et al. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. Br J Cancer 2010;103:1201-8.
4. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR et al. Functional roles for C5a receptors in sepsis. Nat Med 2008;14:551-7.
5. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008;20:518-23.
6. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5.
7. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007;13:2836-48.
8. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004;4:469-78.
9. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007;220:47-59.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
11. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990;11:116-28.
12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229-35.
13. Vangestel C, Van de Wiele C, Mees G, Mertens K, Staelens S, Reutelingsperger C et al. Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99 m tricarbonyl His-annexin A5 in a colorectal cancer xenograft model. Mol Imaging 2012;11:135-47.
14. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
15. Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005;4:1495-504.
16. Hu X, Su F, Qin L, Jia W, Gong C, Yu F et al. Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. Biochem Biophys Res Commun 2006;346:778-85.
17. Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007;30:596-606.